Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 21 (23) 5294-5304
Year:
2015
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
2130 is parent abstract
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
5
Parents:
1003  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
Correl Sci NOS    
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, CA33601, U10 CA031946, U10 CA033601, U10 CA180821, U24 CA114740, CA-114740, CA-25224, U10 CA180850, K05 CA-142885, U10 CA180790, P30 CA015083, U10 CA180882, U24 CA196171, K05 CA142885, U10 CA025224, CA31946  
Corr. Author:
 
Authors:
                   
Networks:
LAPS-MN026, LAPS-OH007   
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
colon cancer, adjuvant, tumor site, BRAF, KRAS, MSI, prognosis